Anne Wojcicki, former 23andMe CEO (Jeff Chiu/AP Images, File)
June 5, 2025 07:15 AM EDTUpdated 11:14 AM
Deals
Pharma

Anne Wo­j­ci­c­ki and Re­gen­eron set to duke it out in restart­ed 23andMe auc­tion

Ayisha Sharma

News Reporter

Anne Wo­j­ci­c­ki, the for­mer CEO of be­lea­guered ge­net­ics test­ing ser­vice 23andMe, isn’t giv­ing up her fight to take back the com­pa­ny she start­ed in her …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Is there still hope for Sum­mit's can­cer drug buried in the da­ta?

Biotech ranks as Chi­na’s best shot to sur­pass US in emerg­ing tech, re­port finds

MIT sci­en­tists’ AI mod­el one-ups Al­phaFold 3, takes on ‘fun­da­men­tal is­sue’ in drug R&D

At a cross­roads, biotechs are pass­ing on re­verse merg­ers in 2025

GSK taps Sanofi vet to lead vac­cine R&D; Bris­tol My­ers names head of cor­po­rate af­fairs

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times